Estimability and interpretation of vaccine efficacy using frailty mixing models

American Journal of Epidemiology

Volumn 144, Issue 1, 1996, Pages 83-97

  Halloran, M Elizabeth ^a   Longini Jr , Ira M ^a   Struchiner, Claudio J ^b  

^a EMORY UNIVERSITY   (United States)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

attributable risk; inference; randomization; study design; survival analysis; vaccines

Indexed keywords

ARTICLE; DISEASE PREDISPOSITION; DRUG EFFICACY; INFECTION; INFECTION RISK; INFECTION SENSITIVITY; VACCINATION;

EID: 0029900224     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a008858     Document Type: Article

References (39)

1. Halloran ME, Cochi SL, Lieu TA, et al. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 1994;140:81-104.
2. Halloran ME, Struchiner CJ. Causal inference for infectious diseases. Epidemiology 1995;6:142-51.
3. Rhodes PH, Halloran ME, Longini IM. Counting process models for differentiating exposure to infection and susceptibility. J R Stat Soc B (in press).
4. Smith PG, Rodrigues LC, Fine PEM. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int J Epidemiol 1984;13: 87-93.
5. Svensson Å. Analyzing effects of vaccines. Math Biosci 1991; 107:407-12.
6. Haber M, Longini IM, Halloran ME. Measures of the effects of vaccination in a randomly mixing population. Int J Epidemiol 1991;20:300-10.
7. Halloran ME, Longini IM, Struchiner CJ, et al. Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field. Stat Med 1994;13:357-77.
8. Aaby P, Jensen TG, Hansen HI, et al. Trials of high-dose Edmonston-Zagreb measles vaccine in Guinea-Bissau: protective efficacy. Lancet 1988;2:809-14.
9. Alonso PL, Smith T, Armstrong Schellenberg JRM, et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994;344:1175-81.
10. Greenwood M, Yule UG. The statistics of anti-typhoid and anti-cholera inoculations, and the interpretation of such statistics in general. Proc R Soc Med 1915;8(pt 2): 113-94.
11. Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis B with vaccine: report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 1982;97:362-6.
12. White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992;11:19-23.
13. Greenland S, Frerichs RR. On measures and models for the effectiveness of vaccines and vaccination programs. Int J Epidemiol 1988;17:456-63.
14. Halloran ME, Haber M, Longini IM Jr. Interpretation and estimation of vaccine efficacy under heterogeneity. Am J Epidemiol 1992;136:328-43.
15. Brunet RC, Struchiner CJ, Halloran ME. On the distribution of vaccine protection under heterogeneous response. Math Biosci 1993;116:111-25.
16. Longini IM, Halloran ME, Haber MJ. Estimation of vaccine efficacy from epidemics of acute infectious agents under vaccine-related heterogeneity. Math Biosci 1993;117:271-81.
17. Longini IM, Halloran ME. A frailty mixture model for estimating vaccine efficacy. Appl Stat 1996;45:165-73.
18. Hougaard P. Life table methods for heterogeneous populations: distributions describing heterogeneity. Biometrika 1984;71:75-83.
19. Hougaard P. Survival models for heterogeneous populations derived from stable distributions. Biometrika 1986;73:671-8.
20. Aalen O. Heterogeneity in survival analysis. Stat Med 1988; 7:1121-37.
21. Aalen O. Modelling heterogeneity in survival analysis by the compound Poisson distribution. Ann Appl Prob 1992;2: 951-72.
22. Hougaard P. Frailty models for survival data. Copenhagen, Denmark: Laegeforeningens Forlag, 1995.
23. Farewell VT. A model for a binary variable with time-censored observations. Biometrika 1977;64:43-6.
24. Farewell VT. The use of mixture models for the analysis of survival data with long-term survivors. Biometrics 1982;38: 1041-6.
25. Kuk AC, Chen C-H. A mixture model combining logistic regression with proportional hazards regression. Biometrika 1992;79:531-41.
26. Ross R. An application of the theory of probabilities to the study of a priori pathometry. Part 1. Proc R Soc Series A 1916;92:204-230.
27. Struchiner CJ, Halloran ME, Robins JM, et al. The behavior of common measures of association used to assess a vaccination program under complex disease transmission patterns - a computer simulation study of malaria vaccines. Int J Epidemiol 1990;19:187-96.
28. Halloran ME, Struchiner CJ. Study designs for dependent happenings. Epidemiology 1991;2:331-8.
29. Cox DR, Oakes D. Analysis of survival data. London, England: Chapman and Hall, 1984.
30. Halloran ME, Haber M, Longini IM Jr, et al. Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol 1991;133:323-31.
31. Vaupel JW, Manton KG, Stallard E. The impact of heterogeneity in individual frailty on the dynamics of mortality. Demography 1979;16:439-54.
32. Vaupel JW, Yashin AI. Some surprising effects of selection on population dynamics. Am Stat 1985;39:176-85.
33. Koopman JS, Longini IM Jr, Jacquez JA, et al. Assessing risk factors for transmission of infection. Am J Epidemiol 1991; 133:1199-209.
34. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh: results from three year follow-up. Lancet 1990;335:270-3.
35. Farewell VT. Mixture models in survival analysis: Are they worth the risk? Can J Statist 1986;14:257-62.
36. Fleming T, Harrington D. Counting processes and survival analysis. New York, NY: Wiley, 1991.
37. Struchiner CJ, Halloran ME, Spielman A. Modeling malaria vaccines I: new uses for old ideas. Math Biosc 1989;94: 87-113.
38. Struchiner CJ, Halloran ME, Brunet RC, et al. Malaria vaccines: lessons from field trials. Cadernos do Saúde Pública 1994;10(Suppl 2):310-26.
39. Hougaard P, Myglegaard P, Borch-Johnsen K. Heterogeneity models of disease susceptibility, with application to diabetic nephropathy. Biometrics 1994;50:1178-88.